| abstract |
A method for the modulation of cellular activity of tissue and cells expressing a high affinity cell-surface receptor for hyaluronic acid, for example an adhesion molecule (for example, ICAM-1, HARLEC and CD44) and a Regulatory molecule (for example, RHAMM) of a human is provided the method comprising the administration of a non-toxic effective amount of a form of hyaluronic acid) (for example, hyaluronic acid, a salt thereof, (for example, sodium hyaluronate having a molecular weight less than 750,000 daltons, (for example, 225,000 daltons), for example from Hyal Pharmaceutical Corporation within the range of 150,000-225,000 daltons and those disclosed in U.S. Patent Application 08/143,983, molecular weight fractions of a form of sodium hyaluronate (for example, fractions disclosed in Canadian Letters Patent 1205031 (to Fidia) such as those from 50,000-100,000 daltons, 250,000-350,000 daltons and 500,000-730,000 daltons, or other fractions, homologues, analogues, derivatives, complexes, esters, fragments and/or sub units of hyaluronic acid and/or combinations thereof) and/or hyaluronic acid mimicking molecules to a human to modulate cellular activity of tissues and/or cells expressing a high affinity cell-surface receptor for hyaluronic acid, for example, an adhesion molecule and a Regulatory molecule in the human body, in a pharmaceutical excipient tolerable by the human (for example, sterile water). |